首页> 美国卫生研究院文献>Clinical Cardiology >The effect of thrombolytic therapy on left ventricular aneurysm formation in acute myocardial infarction: Relationship to successful reperfusion and vessel patency
【2h】

The effect of thrombolytic therapy on left ventricular aneurysm formation in acute myocardial infarction: Relationship to successful reperfusion and vessel patency

机译:溶栓治疗对急性心肌梗死左室动脉瘤形成的影响:与成功的再灌注和血管通畅的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Although there is increasing evidence for the beneficial effect of thrombolytic therapy on global left ventricular (LV) function in acute myocardial infarction (AMI), the data concerning the early effect of thrombolytic therapy on the incidence of left ventricular aneurysm (LVA) formation and its relationship to clinical and angiographic determinants are limited. Hypothesis: The study aimed to determine the independent factors involved in the development of LVA and to evaluate whether thrombolytic therapy has any preventive effect on the development of LVA in AMI. Methods: In all, 350 consecutive patients suffering from a first attack of AMI were included. Of these, 205 who arrived within 12 h of onset of symptoms received thrombolytic therapy (thrombolytic group) and the remaining 145 patients served as control group. All patients received aspirin and maximal‐dose anticoagulation with intravenous heparin therapy. Early successful reperfusion was assessed by enzymatic and electrocardiographic evidence, and late vessel patency was evaluated according to Thrombolysis in Myocardial Infarction (TIMI) classification. Patients with TTMI grade 2 or 3 flow were considered to have vessel patency. Results: The overall incidence of LVA was 11.7% (41/350), and no statistical difference was found between the incidence of LVA between the two groups (11.7 vs. 11.7%, p>0.05). However, the patients receiving thrombolytic therapy and exhibiting a patent infarct‐related artery (PIRA) (n = 125, 61%), had a significantly reduced incidence of LVA compared with those who did not (7.2 vs. 18.8%, p=0.015). In univariate analysis, vessel patency, proximal left anterior descending artery (LAD) stenosis, total LAD occlusion, multivessel disease, and hypertension were found to be important factors in LVA formation after AMI. After adjustment for other clinical and angiographic variables, total LAD occlusion (odds ratio [OR] 3.62,95% confidence interval [CI] 2.45–8.42, p = 0.0014), absence of PIRA (OR 2.92, 95% CI 1.41–09, p = 0.0037) and proximal LAD stenosis (OR 2.11, 95% CI 1.05–4.71, p = 0.045) remained the independent determinants of LVA formation after AMI. Conclusion: Our data indicate that not all patients who received thrombolytic therapy, but only those with PIRA had evidently reduced the incidence of LVA. Patients with total LAD occlusion, with proximal LAD stenosis, and without PIRA were found to have increased risk for formation of LVA after AMI. These findings indicate that the presence of vessel patency has a preventive effect on LVA formation in AMI.
机译:背景:尽管有越来越多的证据表明溶栓治疗对急性心肌梗塞(AMI)的整体左心室(LV)功能有有益作用,但有关溶栓治疗对左心室动脉瘤(LVA)形成发生率早期影响的数据其与临床和血管造影决定因素的关系是有限的。假设:该研究旨在确定与LVA发生有关的独立因素,并评估溶栓治疗是否对AMI中LVA的发生有预防作用。方法:总共包括350例首次发生AMI的连续患者。其中,在症状发作后12小时内到达的205例接受了溶栓治疗(溶栓组),其余145例患者作为对照组。所有患者均接受静脉注射肝素治疗并接受阿司匹林和最大剂量抗凝治疗。早期成功的再灌注通过酶促和心电图证据进行评估,晚期血管通畅根据心肌梗塞溶栓(TIMI)分类进行评估。 TTMI 2或3级血流的患者被视为血管通畅。结果:LVA的总发生率为11.7%(41/350),两组之间LVA的发生率无统计学差异(11.7对11.7%,p> 0.05)。但是,接受溶栓治疗并表现出梗死相关动脉(PIRA)的患者(n = 125,61%)与未接受溶栓的患者相比,LVA的发生率显着降低(7.2 vs. 18.8%,p = 0.015)。 )。在单变量分析中,发现血管通畅,左前降支近端狭窄,总LAD闭塞,多支血管疾病和高血压是AMI后LVA形成的重要因素。调整其他临床和血管造影变量后,总LAD闭塞(比值[OR] 3.62,95%置信区间[CI] 2.45–8.42,p = 0.0014),不存在PIRA(OR 2.92,95%CI 1.41–09, p = 0.0037)和近端LAD狭窄(OR 2.11,95%CI 1.05-4.71,p = 0.045)仍然是AMI后LVA形成的独立决定因素。结论:我们的数据表明,并非所有接受溶栓治疗的患者,只有PIRA患者明显降低了LVA的发生率。发现完全LAD闭塞,近端LAD狭窄且无PIRA的患者在AMI后发生LVA的风险增加。这些发现表明血管通畅的存在对AMI中LVA形成具有预防作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号